tiprankstipranks
Enfusion initiated with a Neutral at JPMorgan
The Fly

Enfusion initiated with a Neutral at JPMorgan

JPMorgan analyst Alexei Gogolev initiated coverage of Enfusion with a Neutral rating and $12 price target. The analyst prefers shares of Clearwater Analytics (CWAN) over Enfusion, citing the former’s proven execution track record and expectation that it may become a Rule of 40 company by 2024. The firm adds that customers of financial services software providers are not immune to macro headwinds and stock market volatility.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on ENFN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles